LiGalli, the company
We’re on a mission to revolutionize women’s healthcare.
We leverage on the knowledge and experience of our partners
Our organization is built upon a team of experts with an extensive network of specialized companies we work with for product development and research.
To fulfill our mission, we partner with the most creative minds and top experts in the field.
Our members
- Team
- Advisors
- Supervisory Board
Bart
van Rossum
CMO
Bart is a passionate leader in medical and pharmaceutical affairs with over a decade of experience in the pharmaceutical sector. He is capable of improving business by creating a clear vision and strategy combined with a strong execution of effective tactics, always with the customer at the centre.
Why
we care
1
Women’s diseases need new attention
Women’s health has been underrepresented in medical investment, research, and innovation.
Medical solutions for women have not yet been fully explored because of still current male-first approach.
2
Existing solutions are not sufficient
Millions of women experience problems, side effects, and intolerability related to current treatments.
Women are 50-75% more likely to have adverse reaction to medications than men.
Certain side effects that are typically experienced with oral drug intake may be reduced through the vaginal route.
3
femtech
offers new
opportunities
The lack of innovation in women’s health has led to current solutions that do not adequately support women.
This gap leads to poorer quality of life and lower health outcomes for women.
Get in touch
Office
Leiden Bio Science Park – BioPartner 1
Address
J.H. Oortweg 21
2333 CH Leiden
The Netherlands
Disclaimer policy
This website of LiGalli B.V., Leiden, The Netherlands, includes forward looking statements.
These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks, evolving uncertainties and change.
There can be no guarantees, with respect to pipeline products, that they will receive necessary regulatory approval nor that they will prove to be commercially successful.
If underlying assumptions might prove to be inaccurate, or risks or uncertainties materialize, actual situations and results may differ materially from those set forth in the forward looking statements in the LiGalli website.